MIRM
Mirum Pharmaceuticals, Inc.
NASDAQ · USHealthcareBiotechnology
$116.62-1.88%
Price as of Jul 20, 2026
MIRM financials
Mirum Pharmaceuticals, Inc. financial statements
Annual and quarterly income statement, balance sheet and cash-flow history. On small screens, start with four periods and expand the table when needed.
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $521.3M | $336.9M | $186.4M | $77.1M |
| Cost of revenue | $100.6M | $81.6M | $47.0M | $12.4M |
| Gross profit | $420.7M | $255.2M | $139.3M | $64.7M |
| Operating expenses | $443.2M | $342.9M | $248.5M | $195.9M |
| Operating income | -$22.1M | -$87.6M | -$109.2M | -$131.2M |
| Net income | -$23.4M | -$87.9M | -$163.4M | -$135.7M |
| EBITDA | $17.2M | -$49.0M | -$136.5M | -$122.9M |
| Basic EPS | $-0.47 | $-1.85 | $-4.00 | $-4.01 |
| Diluted EPS | $-0.47 | $-1.85 | $-4.00 | $-4.02 |
| Balance sheet | ||||
| Cash & equivalents | $296.7M | $222.5M | $286.3M | $28.0M |
| Total assets | $842.8M | $670.8M | $646.6M | $352.9M |
| Total liabilities | $528.1M | $445.1M | $398.0M | $210.9M |
| Stockholders’ equity | $314.7M | $225.6M | $248.7M | $142.0M |
| Total debt | $319.5M | $317.8M | $308.1M | $2.2M |
| Net debt | $22.8M | $95.3M | $21.8M | -$25.8M |
| Cash flow | ||||
| Operating cash flow | $55.8M | $10.3M | -$70.9M | -$120.1M |
| Capital expenditure | -$954.0K | -$993.0K | -$20.1M | -$278.0K |
| Free cash flow | $54.9M | $9.3M | -$91.1M | -$120.4M |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 |
| Share repurchases | $0.00 | $0.00 | $0.00 | $0.00 |